Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilonacept for prophylaxis of gout flares during initiation of allopurinol therapy
2008-007762-39Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rilonacept in gout and acute gout flare (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Number of gout flares per subject from Day 1 to Week 16. Started Mar 2009; status: completed.
02
Drugs
rilonacept
03
Conditions
goutacute gout flare
Beyond the preview
Go deeper on 2008-007762-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007762-39.